<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704937</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-001657</org_study_id>
    <nct_id>NCT01704937</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum</brief_title>
  <official_title>Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a &quot;stool&#xD;
      transplant&quot; from a healthy individual to a C. difficile-infected recipient, and has long been&#xD;
      a successful approach to recurrent/refractory C. difficile. The purpose of this project is to&#xD;
      generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used&#xD;
      repeatedly, particularly in those who do not have a healthy intimate partner or other related&#xD;
      donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by&#xD;
      the nasogastric route. This study will evaluate the safety and secondarily the efficacy of a&#xD;
      frozen inoculum administered by nasogastric tube vs administered by colonoscope.&#xD;
&#xD;
      Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via&#xD;
      either:&#xD;
&#xD;
        -  colonoscopy&#xD;
&#xD;
        -  NGT&#xD;
&#xD;
      The primary endpoint is assessment of safety as measured by clinical events (GI, procedural,&#xD;
      systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C.&#xD;
      difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a&#xD;
      normal bowel status for the individual. Secondary efficacy endpoints include weight,&#xD;
      subjective well-being and relative clinical improvement per standardized questionnaire, and&#xD;
      subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects&#xD;
      will be monitored for clinical safety by history and standard exams and the follow-up&#xD;
      questionnaire as well as followed closely by phone and in person.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 mo post FMT</time_frame>
    <description>Safety is assessed by clinical symptoms, exam, signs (GI and systemic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Colonoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplant (&quot;stool transplant&quot;) from healthy, unrelated donor via colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasogastric Tube (NGT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplant (&quot;stool transplant&quot;) from healthy, unrelated donor via NGT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota Transplant (FMT)</intervention_name>
    <description>Reconstitution of normal flora by a &quot;stool transplant&quot; from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube</description>
    <arm_group_label>Colonoscopy</arm_group_label>
    <arm_group_label>Nasogastric Tube (NGT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent or relapsing CDI defined as EITHER(13):&#xD;
&#xD;
               -  At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper&#xD;
                  with vancomycin with or without an alternative antibiotic (e.g. rifaximin,&#xD;
                  nitazoxanide).&#xD;
&#xD;
               -  At least two episodes of severe CDI resulting in hospitalization and associated&#xD;
                  with significant morbidity.&#xD;
&#xD;
          -  Willingness to accept risk of unrelated donor stool&#xD;
&#xD;
          -  Willingness to be randomized to NGT vs. colonoscopic delivery.&#xD;
&#xD;
          -  Able to consent for self, or parental assent/child assent as age appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anatomic contraindication to NGT&#xD;
&#xD;
          -  Delayed gastric emptying syndrome&#xD;
&#xD;
          -  Known chronic aspiration&#xD;
&#xD;
          -  Contraindication to colonoscopy (ASA 4 or more)&#xD;
&#xD;
          -  High risk of bacterial translocation (Immunosuppression, cirrhosis etc)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Acute unrelated infection or comorbid illness exaccerbation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth L Hohmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014 Jun;58(11):1515-22. doi: 10.1093/cid/ciu135. Epub 2014 Apr 23.</citation>
    <PMID>24762631</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth L. Hohmann, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplant</keyword>
  <keyword>Clostridium difficile</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

